Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL ...

Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs ...

Panelists discuss how dermatologic toxicities from EGFR-targeted therapies can be effectively managed through a comprehensive approach combining prophylactic measures, early interventions with oral ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

"When most people hear the words palliative care, they immediately think about hospice or end-of-life care. This includes ...

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to ...

Lenvatinib showed a median PFS of 5.4 months in advanced HCC patients following treatment with atezolizumab/bevacizumab, meeting the primary endpoint. Second-line ...

Here are the top 5 articles from 2024 reported on Oncology Nursing News. Opinion: The Media May Have Oversold AOH1996, City ...

Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo). The FDA granted approval to ...